Alps Advisors Inc. grew its position in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 32.4% in the 4th quarter, HoldingsChannel reports. The firm owned 41,599 shares of the specialty pharmaceutical company’s stock after buying an additional 10,176 shares during the period. Alps Advisors Inc.’s holdings in Flexion Therapeutics were worth $1,042,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of FLXN. State Street Corp increased its holdings in shares of Flexion Therapeutics by 66.3% during the 2nd quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after purchasing an additional 549,948 shares in the last quarter. Wasatch Advisors Inc. increased its holdings in Flexion Therapeutics by 58.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after acquiring an additional 376,745 shares in the last quarter. Ardsley Advisory Partners purchased a new stake in Flexion Therapeutics in the 2nd quarter worth $3,338,000. Gagnon Securities LLC purchased a new stake in Flexion Therapeutics in the 3rd quarter worth $3,490,000. Finally, Pictet Asset Management Ltd. increased its holdings in Flexion Therapeutics by 27.8% in the 3rd quarter. Pictet Asset Management Ltd. now owns 604,469 shares of the specialty pharmaceutical company’s stock worth $14,616,000 after acquiring an additional 131,673 shares in the last quarter. 73.21% of the stock is owned by hedge funds and other institutional investors.

In other Flexion Therapeutics news, insider Neil Bodick bought 2,700 shares of the company’s stock in a transaction dated Tuesday, November 21st. The stock was acquired at an average price of $24.49 per share, with a total value of $66,123.00. Following the completion of the acquisition, the insider now directly owns 64,605 shares of the company’s stock, valued at $1,582,176.45. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.98% of the stock is owned by corporate insiders.

FLXN has been the subject of several recent analyst reports. Berenberg Bank initiated coverage on shares of Flexion Therapeutics in a report on Thursday, February 1st. They issued a “buy” rating and a $42.00 price target for the company. Wells Fargo & Co set a $39.00 price target on shares of Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, October 30th. Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Royal Bank of Canada set a $44.00 price target on shares of Flexion Therapeutics and gave the stock a “buy” rating in a report on Sunday, October 29th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Flexion Therapeutics has an average rating of “Buy” and an average price target of $99.11.

Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) opened at $21.92 on Friday. The company has a market cap of $800.26, a price-to-earnings ratio of -6.23 and a beta of 0.91. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics Inc has a 1-year low of $16.51 and a 1-year high of $32.25.

COPYRIGHT VIOLATION NOTICE: “Alps Advisors Inc. Purchases 10,176 Shares of Flexion Therapeutics Inc (FLXN)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/alps-advisors-inc-purchases-10176-shares-of-flexion-therapeutics-inc-flxn/1858664.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.